Table 2.
Mean Absolute and Normalized Brain Volume of the Participants. Note that Although there was Brain Atrophy in MS Patients, Compared to Controls, Because of a Reduction in White Matter and Thalami Volumes, there was No Significant Difference in White Matter, Gray Matter, Thalami and Whole-Brain Volumes Between the Two MS Groups.
| Volume | Groups | Mean (Standard Deviation) | P | Pairwise Comparisons (P) |
|---|---|---|---|---|
| White matter (absolute volume – cm3)* | Controls | 487.10 (72.55) | .025 | Controls vs MSuNat – .022 |
| MSuNat | 425.75 (69.76) | Controls vs MSnuNat – .672 | ||
| MSnuNat | 467.97 (73.78) | MSuNat vs MSnuNat – .152 | ||
| White matter (normalized by the total cranial volume - %)* | Controls | 37.20 (2.47) | <.001 | Controls vs MSuNat - <.001 |
| MSuNat | 31.70 (3.90) | Controls vs MSnuNat – .003 | ||
| MSnuNat | 33.47 (3.84) | MSuNat vs MSnuNat – .256 | ||
| Gray matter (absolute volume – cm3)* | Controls | 626.02 (75.30) | .299 | Controls vs MSuNat – .993 |
| MSuNat | 627.34 (59.75) | Controls vs MSnuNat - .372 | ||
| MSnuNat | 653.82 (64.49) | MSuNat vs MSnuNat – .407 | ||
| Gray matter (normalized by the total cranial volume - %)* | Controls | 48.05 (3.96) | .388 | Controls vs MSuNat – .415 |
| MSuNat | 46.85 (2.67) | Controls vs MSnuNat - .429 | ||
| MSnuNat | 46.87 (2.56) | MSuNat vs MSnuNat – .999 | ||
| White matter + gray matter (absolute volume – cm3)* | Controls | 1113.13 (132.36) | .159 | Controls vs MSuNat – .491 |
| MSuNat | 1054.65 (119.86) | Controls vs MSnuNat – .776 | ||
| MSnuNat | 1147.88 (214.96) | MSuNat vs MSnuNat – .170 | ||
| White matter + gray matter (normalized by the total cranial volume - %)* | Controls | 85.26 (3.79) | <.001 | Controls vs MSuNat – <.001 |
| MSuNat | 78.56 (5.10) | Controls vs MSnuNat – .004 | ||
| MSnuNat | 80.35 (5.05) | MSuNat vs MSnuNat – .452 | ||
| Right thalamus volume (absolute volume – cm3)* | Controls | 5.15 (.50) | <.001 | Controls vs MSuNat – <.001 |
| MSuNat | 4.06 (.99) | Controls vs MSnuNat – .02 | ||
| MSnuNat | 4.42 (.87) | MSuNat vs MSnuNat – .36 | ||
| Right thalamus volume (normalized by the total cranial volume - %)* | Controls | .39 (.03) | <.001 | Controls vs MSuNat – <.001 |
| MSuNat | .30 (.06) | Controls vs MSnuNat – <.001 | ||
| MSnuNat | .31 (.06) | MSuNat vs MSnuNat – .63 | ||
| Left thalamus volume (absolute volume – cm3)* | Controls | 5.15 (.49) | .004 | Controls vs MSuNat – .02 |
| MSuNat | 4.15 (1.08) | Controls vs MSnuNat – .025 | ||
| MSnuNat | 4.38 (.97) | MSuNat vs MSnuNat – .70 | ||
| Left thalamus volume (normalized by the total cranial volume - %)* | Controls | .39 (.03) | <.001 | Controls vs MSuNat – <.001 |
| MSuNat | .30 (.06) | Controls vs MSnuNat – <.001 | ||
| MSnuNat | .31 (.06) | MSuNat vs MSnuNat – .93 |
MSuNat = multiple sclerosis patients using natalizumab; MSnuNat = multiple sclerosis patients not using natalizumab. Statistical analysis used: *: ANOVA with post hoc Bonferroni.